Drug Type Small molecule drug |
Synonyms Terevalefim + [2] |
Target |
Mechanism c-Met agonists(Hepatocyte growth factor receptor agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC9H8N2S |
InChIKeyFOHWAQGURRYJFK-ONEGZZNKSA-N |
CAS Registry1070881-42-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Kidney Injury | Phase 3 | GE | 24 Feb 2017 | |
Acute Kidney Injury | Phase 3 | US | 24 Feb 2017 | |
Acute Kidney Injury | Phase 3 | CA | 24 Feb 2017 | |
Delayed Graft Function | Phase 3 | US | 01 Mar 2016 | |
Functional disorder | Phase 3 | US | 01 Mar 2016 | |
ST Elevation Myocardial Infarction | Phase 3 | US | 01 Jul 2012 | |
Death, Sudden, Cardiac | Phase 3 | NL | 01 Aug 2011 | |
Death, Sudden, Cardiac | Phase 3 | ES | 01 Aug 2011 | |
Death, Sudden, Cardiac | Phase 3 | GB | 01 Aug 2011 | |
Renal injury | Phase 3 | US | 01 Feb 2010 |
NCT02474667 (Pubmed) Manual | Phase 3 | 248 | (epozpzwsvj) = not significantly different between the ANG-3777 and placebo groups. qmrgafiips (zqwbjllsrp ) | Negative | 20 Feb 2024 | ||
Placebo | |||||||
Phase 2 | 275 | (ytkxvgrdrb) = pgwwycxisc ucbcqrmuke (rrlyxbfate ) View more | Negative | 09 Dec 2021 | |||
Placebo | (ytkxvgrdrb) = gvaxhkdnjh ucbcqrmuke (rrlyxbfate ) View more | ||||||
Phase 3 | 253 | (pldnweypol) = hgzuybujqd jjchvxeubg (pllxsvbcpk ) | Negative | 26 Oct 2021 | |||
Placebo | (pldnweypol) = jtrwdjkbss jjchvxeubg (pllxsvbcpk ) | ||||||
Phase 2/3 | - | (mosravqwoz) = ksaasqsden pnxvyprzyr (vcmvdtktyq ) View more | Positive | 03 Nov 2015 | |||
(mosravqwoz) = dfntmpcqyd pnxvyprzyr (vcmvdtktyq ) |